Press Room

Press Release / Sep 24, 2025

Hovione and Microinnova partner to advance modular flow chemistry for multi-purpose manufacturing

Collaboration unlocks multi-purpose capabilities to accelerate small molecule production

Hovione and Microinnova collaboration
  • Collaboration unlocks multi-purpose capabilities to accelerate small molecule production
  • Modular approach enables faster process transfer, sustainable operations, and fully integrated development solutions

Lisbon, Portugal, 24 September 2025 – Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a recognized leader in continuous process intensification, today announced a partnership to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry.
The companies will work together to test Microinnova’s modular manufacturing equipment in an industrial setting. The Microinnova equipment is designed to offer greater flexibility, easier scalability, enhanced efficiency and sustainable practices in active ingredient production. Together, the companies are aiming at faster process development, simple transition from lab to large-scale manufacturing, and ultimately decreased time to market for pharmaceutical customers.

"This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.”

Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova. “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”

 

About Hovione 
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

About Microinnova
Microinnova provides process development as well as successful pilot plant & manufacturing plant solutions. Based on more than 20 years of experience in flow chemistry & process intensification and 250+ successfully completed projects, Microinnova is the partner of choice for continuous manufacturing.  Microinnova’s team uses process intensification techniques and selects the most advantageous technology for each process, even in regulated environments. As an ISO 9001:2015-certified company, Microinnova designs plants that meet GMP and ATEX standards for quality and safety. Specializing in modular continuous plants, Microinnova scales processes from lab tests to tons-per-hour production, enabling rapid time-to-market and flexibility. For more information, please visit microinnova.com

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026